ReviewCurrent opinion in nephrology and hypertension2018
Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures.
Review in Current opinion in nephrology and hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Trial
- Sustained Improvements After Intervention to Prevent Contrast-Associated Acute Kidney Injury: A Randomized Controlled Trial.Journal of the American Heart Association · 2025Trial
- Impact of contrast volume on medium- to long-term renal function in patients undergoing repeated percutaneous coronary interventions.International journal of cardiology. Heart & vasculature · 2026Article
- Time To Inject Some Contrast into the Nephrotoxicity Debate.Kidney360 · 2026Article
- Beyond guesswork: addressing the wide variability in pediatric iodinated contrast media delivery from an international perspective.Pediatric radiology · 2026Article
- [Biomarkers of oxidative stress and inflammation in contrast-associated acute kidney injury].Anales del sistema sanitario de Navarra · 2024Article
- Iodine contrast should be avoided in patients with thyroid eye disease.Frontiers in ophthalmology · 2024Article
- Society of Chest Imaging and Interventions Consensus Guidelines for the Interventional Radiology Management of Hemoptysis.The Indian journal of radiology & imaging · 2023Review
- Effectiveness of Inferior Mesenteric Artery Embolization on Type II Endoleak-Related Complications after Endovascular Aortic Repair (EVAR): Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Canadian Association of Radiologists Guidance on Contrast-Associated Acute Kidney Injury.Canadian journal of kidney health and disease · 2022Article
- Truncus Bicaroticus With Arteria Lusoria: A Rare Combination of Aortic Root Anatomy Complicating Cardiac Catheterization.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- Contrast-associated acute kidney injury following peripheral angiography.Proceedings (Baylor University. Medical Center) · 2021Article
- Successful Revascularization of Infrapopliteal Chronic Total Occlusions Using the Plantar Arch as a Conduit and Retrograde Pedal Access.Ochsner journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
purpose of reviewContrast-induced acute kidney injury (CI-AKI) is a serious complication. Although nonmodifiable and modifiable risk factors have been thoroughly characterized, the utility of the maximal allowable contrast dose (MACD) has not received adequate attention. The focus of this review is to provide a critical appraisal of this modifiable risk factor. RECENT
findingsSeveral retrospective and prospective cohort studies have demonstrated that the incidence of CI-AKI among patients receiving contrast media in volumes exceeding the MACD is consistently higher compared with those who do not exceed the MACD (an average of 24 vs. 6%). Furthermore, the MACD is independent predictor of CI-AKI and other adverse events. A two-step algorithm incorporating the determination of the MACD and the contrast volume to eGFR ratio prior to a planned cardiovascular procedure is a sound approach to minimize contrast volume and prevent CI-AKI. SUMMARY: Prevention of CI-AKI must remain a clinical priority. Intraprocedural preventive measures should include a priori calculation of the MACD and contrast volume to eGFR ratio to limit contrast volume. Other measures may include the adoption of the transradial approach, the use of automated contrast injectors and small catheters to limit contrast volume, the use of low-osmolar contrast agents, and if necessary the use of staged procedures. We call for the system-wide implementation of evidence-based care bundles to prevent CI-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.